Evidence map›Paper›PMID 40614035›Full record

Trial reportAnnals of nuclear medicine2025

Same-day dual-tracer PET/CT imaging with [

Hongyan Li, Chongjiao Li, Yueli Tian, Zhiwei Xiao, Diankui Xing, Yong He

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05034146 (The Diagnostic Efficiency of 68Ga-FAPI PET/CT in Malignant Tumors), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05034146 narecruitingnot on this map

The Diagnostic Efficiency of 68Ga-FAPI PET/CT in Malignant Tumors

TypeinterventionalSponsorZhongnan HospitalRan2021 to 2025Enrolled500ConditionsFibroblast Activation Protein Inhibitor, PET/CT, Malignant NeoplasmArms68Ga-FAPI, PET/CT
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hongyan LiDepartment of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Chongjiao LiDepartment of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Yueli TianDepartment of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Zhiwei XiaoDepartment of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Diankui XingDepartment of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Yong HeDepartment of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China. vincentheyong@163.com.

Funding

National Natural Science Foundation of China 82171986National Natural Science Foundation of China 82372005National Natural Science Foundation of China 82402337the Fundamental Research Funds for the Central Universities 2042023kf0062the Improvement Project for Theranostic Ability on Difficulty Miscellaneous Disease ZLYNXM202007
6 · The paper itself

Abstract

objectiveGallium-68-labelled fibroblast activation protein inhibitor ([

methodsPatients with negative or equivocal [

resultsForty-four patients were included in the analysis. The mFAPI PET was superior to [

conclusionsA same-day dual-tracer PET/CT protocol with [

trial registrationNCT05034146. Registered February 23, 2021.

Indexed as

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyAdultAgedAged, 80 and overFemaleGallium RadioisotopesHumansMaleMiddle AgedNeoplasmsQuinolinesRadioactive TracersTime Factors68Ga-FAPIFluorodeoxyglucose F18Gallium RadioisotopesQuinolinesRadioactive Tracers[18F]FDG[68 Ga]Ga-FAPI-04Dual-tracer PET/CTNegative or equivocal imaging finding

Identifiers

PMID40614035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.